Bristol-Myers Squibb Co. (BMY)

The global bile duct cancer market is projected to expand from $2.59 billion in 2025 to $3.89 billion by 2030, growing at an 8.4% CAGR. Growth is driven by advancements in early diagnostics, increased adoption of immunotherapy and targeted therapies, AI-assisted diagnostics, and rising prevalence of liver diseases. Major pharmaceutical companies are introducing innovative treatments and forming strategic partnerships to enhance patient outcomes.

GlobeNewswire Inc.•Researchandmarkets.Com

Mar 30

The global esophageal cancer market is projected to grow at a CAGR of 9.5% from $1.65 billion in 2026 to $2.37 billion by 2030, driven by advancements in precision oncology, immunotherapies, and minimally invasive procedures. Major pharmaceutical companies including Pfizer, Roche, and Merck are leading the market through product innovation and personalized cancer care solutions.

GlobeNewswire Inc.•Researchandmarkets.Com

Mar 30

AbbVie and Bristol Myers Squibb are highlighted as exceptions in the healthcare sector, offering above-average dividend yields and consistent dividend growth. AbbVie, a Dividend King with a 3.4% yield, has successfully transitioned from its blockbuster drug Humira to new treatments Skyrizi and Rinvoq. Bristol Myers Squibb, yielding 4.4%, is navigating patent cliffs through innovation in its oncology portfolio, making both attractive for patient, buy-and-hold dividend investors.

The Motley Fool•Eric Volkman

Mar 24

Bristol Myers Squibb offers an attractive 4.4% dividend yield and has raised dividends for 17 consecutive years, but the author recommends against buying due to significant patent cliffs on key drugs like Eliquis and Opdivo. With revenue expected to decline from $48.2 billion to $46-47.5 billion, there is substantial uncertainty about the company's ability to maintain its dividend payments in the coming years.

The Motley Fool•David Jagielski, Cpa

Mar 23

The FDA approved Bristol Myers Squibb's Opdivo (nivolumab) combined with chemotherapy (AVD) for previously untreated Stage III or IV classical Hodgkin lymphoma in patients 12 years and older. The approval was based on Study CA209-8UT showing superior progression-free survival with a hazard ratio of 0.42. Despite the regulatory win, BMY stock declined 1.33% to $57.34 on the announcement day.

Benzinga•Vandana Singh

Mar 20

CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.

GlobeNewswire Inc.•Cytomx Therapeutics, Inc.

Mar 18

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.

Benzinga•Gav Blaxberg

Mar 17

The article recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a defensive investment option, highlighting its combination of solid growth (averaging over 13% annual gains over the past decade) and a 3.3% dividend yield. The author suggests that investing $100 monthly could grow to approximately $68,730 in 20 years with a 10% annual return, making it suitable for investors seeking both capital appreciation and regular income in uncertain economic times.

The Motley Fool•Selena Maranjian

Mar 15

The Schwab U.S. Dividend Equity ETF (SCHD) offers a diversified portfolio of 101 high-quality dividend stocks with only 8.2% technology exposure, making it an attractive hedge against AI disruption. The ETF yields about 3.4% and holds blue-chip companies like Lockheed Martin, ConocoPhillips, Chevron, and Verizon Communications, positioning it as a buy-and-hold investment for passive income seekers.

The Motley Fool•Justin Pope

Mar 14

BioNTech shares fell 14.25% in premarket trading after co-founders Ugur Sahin and Özlem Türeci announced plans to transition to a new mRNA venture by end of 2026. The company also lowered 2026 sales guidance to $2.33-$2.68 billion due to declining COVID-19 vaccine demand, though it expects multiple late-stage oncology data readouts in 2026.

Benzinga•Vandana Singh

Mar 10